E. James Song, MD, FAAD, provides key takeaways on the treatment of patients with plaque psoriasis, highlighting ways to define treatment success and the effect of adverse events on long-term treatment choices.

A dermatologist shares perspectives on patient-specific factors that impact treatment decisions in plaque psoriasis.

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

Panelists discuss how research in pediatric psoriasis management needs more attention on long-term safety, treatment efficacy, and the psychosocial impact of the disease on young patients.

An expert on plaque psoriasis provides an overview of systemic therapy options and provides clinical insights on patient monitoring practices and best courses of action when treatment response isn’t sustained.

E. James Song, MD, FAAD, presents a case of a 58-year-old patient with location-specific mild-to-moderate plaque psoriasis.

Panelists discuss how to optimize plaque psoriasis treatment in a 32-year-old man, with a specific focus on addressing genital plaques to enhance patient comfort and improve overall treatment outcomes.

Panelists discuss how to develop tailored treatment approaches for a 34-year-old African American woman with plaque psoriasis, focusing on exploring nonsystemic options that consider her specific demographic and clinical profile.

Panelists discuss how to effectively manage plaque psoriasis in a 55-year-old man by evaluating and potentially combining topical treatments with systemic therapies for optimal disease control.

Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.

Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.

Panelists discuss how novel treatment mechanisms, efficacy assessments, and improved patient engagement strategies are shaping the evolving landscape of vitiligo management.

Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.

A dermatologist provides clinical insights on navigating dose escalation and insurance barriers for patients receiving treatment for plaque psoriasis.

Continuing discussion on a case of a 45-year-old patient with plaque psoriasis, E. James Song, MD, FAAD, discusses management strategies for patients with mild-to-moderate plaque psoriasis.

Brad Glick, DO, MPH, discusses common challenges clinicians may encounter with photodynamic therapy (PDT) and offers resolution strategies, while also sharing insights on the skin conditions and patient populations where PDT has proven to be a successful treatment option.

Brad Glick, DO, MPH, discusses how to effectively introduce photodynamic therapy (PDT) into a dermatology clinic by outlining necessary equipment and setup, providing guidance on essential patient discussions for treatment introduction, and sharing strategies to ensure treatment efficacy while prioritizing patient safety and satisfaction.

Brad Glick, DO, MPH, discusses how photodynamic therapy (PDT) serves as an effective treatment for various skin conditions, highlighting the specific patient populations that are most likely to benefit from this innovative approach.

Panelists discuss how to address treatment challenges and manage site-specific concerns in vitiligo patients, drawing on expert insights and clinical experience.